Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CREDIT-5
CTR20260581Phase 3Active
- Sponsor
- InnoCare Pharma
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tafolecimab in hypercholesterolemia, combined dyslipidaemia, sponsored by InnoCare Pharma. Started Apr 2026; status: active.
02
Drugs
tafolecimab
03
Conditions
hypercholesterolemiacombined dyslipidaemia
Beyond the preview
Go deeper on CTR20260581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260581.